Evidence map›Paper›PMID 25549724›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2015

Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein.

Murali Janakiram, Jordan M Chinai, Susan Fineberg, Andras Fiser, Cristina Montagna, Ramadevi Medavarapu, Ekaterina Castano, Hyungjun Jeon, Kim C Ohaegbulam, Ruihua Zhao and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

113 citing papers in PubMed, 2 syntheses or guidelines pooled it, 151 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

53 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Murali JanakiramDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York. Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
Jordan M ChinaiDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York.
Susan FinebergDepartment of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
Andras FiserDepartment of System and Computational Biology, Biochemistry, Albert Einstein College of Medicine, Bronx, New York.
Cristina MontagnaDepartment of Genetics, Albert Einstein College of Medicine, Bronx, New York.
Ramadevi MedavarapuDepartment of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
Ekaterina CastanoDepartment of Pathology, Yale New Haven Hospital, New Haven, Connecticut.
Hyungjun JeonDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York.
Kim C OhaegbulamDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York.
Ruihua ZhaoDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York.
Aimin ZhaoDepartment of Obstetrics and Gynecology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Steven C AlmoDepartment of Biochemistry, Physiology and Biophysics, Albert Einstein College of Medicine, Bronx, New York.
Joseph A SparanoDepartment of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York. xing-xing.zang@einstein.yu.edu jsparano@montefiore.org.
Xingxing ZangDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York. Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York. xing-xing.zang@einstein.yu.edu jsparano@montefiore.org.
Albert Einstein College of Medicine · USRenji Hospital · CNYale New Haven Hospital · US

Funding

WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI THOMAS E ROHAN · 1985 to 2026
$111.2M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007288 · NIGMS · YESHIVA UNIVERSITY · PI AKABAS, MYLES H. · 1985 to 2022
$35.6M
Stable Isotope and Metabolomics CoreP60DK020541 · NIDDK · YESHIVA UNIVERSITY · PI FLEISCHER, NORMAN S. · 1986 to 2014
$29.8M
Immunology/Pathology CoreP30AI051519 · NIAID · YESHIVA UNIVERSITY · PI GOLDSTEIN, HARRIS · 2003 to 2013
$18.6M
Einstein's Nathan Shock Center of Excellence in Basic Biology of AgingP30AG038072 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI BARZILAI, NIR J · 2010 to 2024
$10.8M
Clinical and Translational Science Award (UL1)UL1TR000086 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SHAMOON, HARRY · 2012 to 2013
$5.5M
Tumor-expressed immune checkpoint B7x-mediated resistance to anti-CTLA-4 therapy.R01CA175495 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI ZANG, XINGXING · 2014 to 2025
$5.1M
Tumor expressed B7x accelerates disease and is a novel target for immunotherapyF31CA183493 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI OHAEGBULAM, KIM C · 2014 to 2017
$193k
NCATS NIH HHS UL1 TR000086NCI NIH HHS F31 CA183493NCI NIH HHS F31CA183493NCI NIH HHS P30 CA013330NCI NIH HHS P30CA013330NCI NIH HHS R01 CA175495NCI NIH HHS R01CA175495NIAID NIH HHS P30 AI051519NIA NIH HHS P30 AG038072NIA NIH HHS P30AG038072NIDDK NIH HHS P60 DK020541NIDDK NIH HHS P60DK020541NIGMS NIH HHS T32 GM007288NIGMS NIH HHS T32GM007288
6 · The paper itself

Abstract

purposeHHLA2 (B7H7/B7-H5/B7y) is a newly identified B7 family member that regulates human T-cell functions. However, its protein expression in human organs and significance in human diseases are unknown. The objective of this study was to analyze HHLA2 protein expression in normal human tissues and cancers, as well as its prognostic significance, to explore mechanisms regulating HHLA2 expression, and to identify candidate HHLA2 receptors. EXPERIMENTAL

designAn immunohistochemistry protocol and a flow cytometry assay with newly generated monoclonal antibodies were developed to examine HHLA2 protein. HHLA2 gene copy-number variation was analyzed from cancer genomic data. The combination of bioinformatics analysis and immunologic approaches was established to explore HHLA2 receptors.

resultsHHLA2 protein was detected in trophoblastic cells of the placenta and the epithelium of gut, kidney, gallbladder, and breast, but not in most other organs. In contrast, HHLA2 protein was widely expressed in human cancers from the breast, lung, thyroid, melanoma, pancreas, ovary, liver, bladder, colon, prostate, kidney, and esophagus. In a cohort of 50 patients with stage I-III triple-negative breast cancer, 56% of patients had aberrant expression of HHLA2 on their tumors, and high HHLA2 expression was significantly associated with regional lymph node metastasis and stage. The Cancer Genome Atlas revealed that HHLA2 copy-number gains were present in 29% of basal breast cancers, providing a potential mechanism for increased HHLA2 protein expression in breast cancer. Finally, Transmembrane and Immunoglobulin Domain Containing 2 (TMIGD2) was identified as one of the receptors for HHLA2.

conclusionsWide expression of HHLA2 in human malignancies, together with its association with poor prognostic factors and its T-cell coinhibitory capability, suggests that the HHLA2 pathway represents a novel immunosuppressive mechanism within the tumor microenvironment and an attractive target for human cancer therapy.

Indexed as

3T3 CellsAmino Acid SequenceAnimalsCD28 AntigensCell Line, TumorDNA Copy Number VariationsFemaleGene ExpressionGlycosylationHumansImmunoglobulinsLymphatic MetastasisMiceMiddle AgedMolecular Sequence DataProtein Processing, Post-TranslationalCD28 AntigensHHLA2 protein, humanImmunoglobulinsTMIGD2 protein, human

Identifiers

PMID25549724
PMCPMC4433806
OpenAlexW2133125158

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.